EGFR and non-small cell lung carcinoma: Although several trials established EGFR tyrosine kinase inhibitor (TKI) therapy as standard treatment for EGFR-positive NSCLC patients [5–8], the median progression-free survival (PFS) was approximately 1 year as a result of acquired TKI therapeutic resistance [5–10].